- Healthcare Mixed Signals: M&A, Policy, Bankruptcies - Jul 21M&A and clinical wins are vying with policy headwinds and operational stress in healthcare today. You’ll want to watch the Tempus-Personalis deal, Medicare policy fights, Latigo’s IPO plans, and a fresh data breach for $CLOV.
- Healthcare: M&A, Policy Pressure & Risks - Jul 20Today’s Healthcare wrap covers a flurry of M&A and tech investments alongside rising regulatory and safety concerns. Read on to see what moved markets and what you should watch tomorrow.
- Healthcare Faces Policy, Access and Safety Risks - Jul 20A mix of public-health scares, policy friction and cost scrutiny is pressuring the healthcare sector this morning. Read on for the headlines, investor implications, and what you should watch today.
- Healthcare Roundup - Jul 19Research on pregnancy weight gain and a preclinical DNA-delivered immunotherapy led headlines. Policy debates on screening, primary care and air quality add mixed signals as markets reopen Monday.
- Healthcare Pulse: Policy, M&A, Research - Jul 19This weekend healthcare headlines mixed policy, M&A and research developments. From federal housing and lead exposure to a Jasper lifeline and mRNA patent suits, find what matters heading into July 20.
- Healthcare Sector Wrap - Jul 18Mixed public-health alerts, policy moves, and selective biotech progress shaped the healthcare story over the holiday weekend. Read the key developments, market context, and what to watch heading into Monday.
- Healthcare Roundup: Policy, M&A & Research - Jul 18A mix of policy action, M&A relief for a struggling biotech, and new research on brain and heart health set the tone heading into the long weekend. Analysts note both growth catalysts and legal and social risks to watch.
- Healthcare Mixed Signals on Innovation, Policy - Jul 17Innovation and policy drove headlines in healthcare today, from a new whole-body cancer imaging method to congressional action on provider pay. You get a mix of scientific wins, corporate restructurings, and regulatory friction to monitor.
- Healthcare Snapshot: Lilly Deal, Policy Noise - Jul 17Lilly's $2.8B purchase of AtaiBeckley and fresh neuroscience and rehab tech research headline a day of mixed signals. Policy fights over prior authorization and Medicaid add uncertainty for payers and providers.
- Healthcare Momentum: Big Pharma Deals and Approvals - Jul 16Lilly's $2.8B psychedelics buyout, Merck's first-in-class PCSK9 pill approval and upbeat biotech trial data led today's healthcare headlines. Funding and policy news add texture for you going into tomorrow.
- Healthcare: CMS, Costs and Legal Wins - Jul 16CMS signaled a possible overhaul of how clinical software and AI get paid, while a Missouri ballot raises tax risk for medical services. Legal wins for HaloMD and new public-health data add nuance for investors.
- Healthcare Momentum on Data, Approvals - Jul 15Today brought forward-looking clinical wins, an FDA approval, and fresh IPO filings that kept biotech momentum alive. You should watch launch details, regulatory politics, and upcoming data readouts.
- Healthcare Roundup - Jul 15Regulatory scrutiny of Medicare Advantage and a PBM settlement headline a mixed morning for healthcare. M&A in digital therapeutics and new drug licensing add growth cues while public health studies spotlight long-term risks.
- Healthcare Wrap-Up - Jul 14Today brought a mix of headwinds and selective wins across healthcare. HCA trimmed 2026 guidance after a $400M payer-mix hit, while biotechs raised fresh capital and new research highlighted clinical tools and risks.
- Healthcare Snapshot: FDA, AI, M&A - Jul 14Regulatory scrutiny and enforcement sit alongside fresh scientific wins and steady hospital dealmaking. Today’s briefing parses FDA criticism, new diagnostics, AI results and what could move stocks.
- Healthcare Wrap-Up Jul 13Clinical wins and stronger diagnostic data led the headlines today, with Freenome results and biotech study rebounds drawing investor attention. Policy and payer stories added caution, so stay selective as you watch upcoming catalysts.
- Healthcare: Cancer Breakthrough and Policy Risks - Jul 13A major advance in pancreatic cancer research sparks excitement while Medicaid funding fights, caregiver cuts, and rising dementia trends temper the outlook. Your guide to what matters in healthcare today.
- Healthcare Wrap-Up Jul 12Preclinical menin inhibition offers a potential oncology avenue while new menopause guidance and lifestyle research keep public-health themes in focus. Markets were closed Sunday; note developments heading into Monday.
- Healthcare Snapshot - Jul 12A mix of clinical wins, program cuts and policy moves shaped the healthcare beat over the weekend. Read what mattered and what you should watch heading into next week.
- Healthcare Wrap-Up: AI, GLP-3, Policy Jul 11AI and drug-design advances and a major GLP-3 phase 3 win dominated the headlines, but policy moves, program cuts and strikes temper the mood. Read a practical summary of implications heading into the next session.
- Healthcare Roundup - Jul 11Clinical wins and policy headwinds shape this weekend's healthcare headlines. Read how a new lung cancer result, strikes, regulatory risks, and public-health studies could affect the sector heading into next week.
- Healthcare Wrap Jul 10: Clinical Wins, Policy HeadwindsClinical breakthroughs and biotech wins competed with policy and provider stress today. Read a concise wrap of trial progress, regulatory risks, strikes, and a major legal settlement that could shape near-term healthcare moves.
- Healthcare Roundup: Key Developments - Jul 10Mixed clinical wins and policy shifts mark today’s healthcare tape. Clinical wins in neonatal care and sleep research sit alongside insurer pressures and a major Roche pipeline cut.
- Healthcare Faces Clinical Setbacks - Jul 9 WrapClinical disappointments and a corporate lawsuit set a cautious tone for healthcare on Jul 9. Research wins and new federal funding offer long-term upside, but near-term headwinds persist.
- Healthcare Faces Trial Setback, System Strain - Jul 9AstraZeneca and Ionis reported a major heart-disease trial failure this morning, while public-health strains and policy pressures add to investor uncertainty. Read what moved markets overnight and what you should watch today.
- Healthcare Sector Faces Headwinds - Jul 8Policy and cost pressures set the tone across healthcare on Jul 8, with ACA premium hikes, a major hospital nurses strike and insurer program exits. Data gaps and wearable hurdles add to the near-term uncertainty.
- Healthcare: Insurers, Gene Therapy and AI - Jul 8Insurers seek a 14% median ACA premium hike as enrollment slips, while biotechs score scientific wins and a $400M funding pact for eye gene therapy. Regulatory and access risks keep the sector mixed.
- Healthcare: Mixed Wins and Risks - Jul 7 WrapBiotech funding and an FDA approval drove positive headlines today, while cyberattacks, policy pressure and safety flags kept a lid on exuberance. Read what moved the sector, what to watch next, and how these developments could affect markets tomorrow.
- Healthcare Roundup: Jul 7 Morning BriefingToday's healthcare news mixes strong R&D advances in neurology and cardiology with sharp policy and insurance pain points. You’ll want to weigh scientific momentum against affordability and coverage risks.
- Healthcare Wrap Jul 6 - Mixed Signals for InvestorsToday’s healthcare headlines mixed strong biotech financing and an IPO filing with policy pressure on drug payments and clinical oversight concerns for GLP-1 telehealth scripts. You’ll find what moved stocks, key research takeaways, and the catalysts to watch tomorrow.
- Healthcare: Policy and AI Crossroads - Jul 6A new Medicaid work rule and a high‑stakes California governor race collide with rising AI adoption and modular construction trends. Here’s what you need to know before the open.
- Healthcare Advances in Care and Therapies - Jul 5Research out of ESMO and academic centers delivered a trifecta of positive news for healthcare: a rehab program easing long COVID brain fog, genetic prediction for glaucoma, and promising early pancreatic cancer therapy data. Heading into the holiday week, these findings reinforce demand for diagnostics, rehab services, and targeted oncology R&D.
- Healthcare Morning Briefing - Jul 5A Europe survey backing state-funded fertility care meets U.K. research on persistent childhood trauma and U.S. warnings about child drownings. Heading into the July 6 session, the news creates mixed signals for healthcare investors.
- Healthcare Roundup Jul 4Research on childhood trauma, rising child drowning concerns, VR perception studies, and coverage of healthcare costs framed the sector narrative heading into the long weekend. Read what you should watch when markets reopen.
- Healthcare Policy, Funding & Public Health - Jul 4Regulatory fights over 340B discounts and a legal loss for Elevance set a cautious tone heading into the long weekend. At the same time, a $180M biotech raise and improved health data flows offer offsetting positives.
- Healthcare Wrap: Policy, Research & Funding - Jul 3Regulatory moves on 340B, Elevance's $115M dispute with CMS, and fresh biotech funding led headlines, while new research on immune signals and heart attack risk added clinical momentum. Markets were closed heading into the long weekend.
- Healthcare Headlines - Jul 3Mixed signals hit healthcare as promising ALS research and a big IPF financing clash with renewed 340B policy fights and an insurer lawsuit. Public health outbreaks add a cautionary note heading into the long weekend.
- Healthcare Wrap: Policy, M&A, Drug Wins - Jul 2Policy moves on 340B and a high-profile Medicare tussle dominated the tape, while Roche posted a phase 3 win and a PureTech-backed startup raised $180M. Read what matters for your portfolio.
- Healthcare Mixed Signals - Jul 2Outbreaks and regulatory gaps clash with promising research and AI-enabled devices. This morning's briefing explains what you need to know, from West Nile to GLP-1s and BCG findings.
- Healthcare: Trials, M&A and Policy Hits - Jul 1Clinical progress, an $800M deal and major policy signals set a mixed tone for healthcare stocks today. Read how trial data, acquisitions and Medicare GLP-1 exposure could affect companies and your watchlist.
- Healthcare: GLP-1 Wins, Biotech Deals - Jul 1New data links GLP-1 drugs to fewer deaths and amputations, while biotech funding, acquisition activity and FDA pilot programs are moving deals and pipelines. Policymakers and payers remain key catalysts to watch.
- Healthcare Wrap: Mixed Wins and Risks - Jun 30Biotech approvals, big venture funding, and new AI tools for pharma stood out today, but a Marburg outbreak and Medicaid legal fights keep risk elevated. Read what matters for your watchlist.
- Healthcare Morning Brief - Jun 30Today’s Healthcare briefing balances lab and clinical wins with policy and enrollment headwinds. Read on for clinical trial updates, a $929M buyout, TEFCA oversight, and what you should watch.
- Healthcare Wrap: Policy, M&A & Breakthroughs - Jun 29Today brought a mixed bag for healthcare: a $929M buyout after clinical setbacks, nearly 3M fewer ACA enrollees, and fresh innovation from biodegradable sensors and lung leukemia research. Read what moved the sector and what you should watch next.
- Healthcare Mixed Signals on Access and AI - Jun 29Today’s healthcare headlines balance troubling access stories with upbeat tech and care-model developments. From uninsured gunshot discharges to AI tools reaching 100,000 clinicians, here’s what you need to know.
- Healthcare Wrap-Up Jun 28Researchers find a way to reverse chemo resistance in ovarian cancer while public-health pieces on melatonin, breastfeeding and sunscreen policy spark debate. Policy and access issues keep the picture mixed for healthcare investors.
- Healthcare Roundup: FDA, BIO Takeaways - Jun 28Regulatory momentum met policy friction over the weekend: FDA accepted a Replimune filing and Merck KGaA made an $11B move, while Medicaid hearings, China deal tensions and access issues remind you to be selective.
- Healthcare Wrap - Jun 27Biotech filings and big corporate deals drew attention heading into the long weekend, even as regulatory, legal and access issues kept risk elevated. Read what matters for your watchlist.
- Healthcare Wrap: Shortages, AI, FDA Moves - Jun 27Drug shortages and regulatory tensions dominated headlines as BIO 2026 highlighted AI and policy risks. Read how FDA filings, M&A and public health studies could affect the sector heading into the long weekend.
- Healthcare Wrap: FDA Filings, BIO Tensions - Jun 26Regulatory moves and policy debates set the tone for healthcare on Jun 26. FDA acceptance and major M&A deals shared the stage with BIO conference tensions and fresh clinical findings you should know.